



#42028

**DATE:**                         **OCTOBER 20, 2017**

**SUBJECT:**                    **NDRM OPTIONS - EXPIRATION PRICING CONSIDERATION**

NDRM (Adjusted NeuroDerm Ltd. options) will be subject to special pricing consideration in expiration processing on October 20, 2017. The pricing consideration is due to the undetermined net cash merger consideration amount included in the option deliverable of NDRM as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

**NDRM**

NDRM options are adjusted NeuroDerm Ltd. options, adjusted October 18, 2017, (see OCC Information Memo #42014). The deliverable of NDRM options is:

**NEW DELIVERABLE  
PER CONTRACT:**                 \$3,900.00 Cash (\$39.00 x 100), less withholdings, if any

As of October 20, 2017, the NDRM Exchange Agent has not determined the final net cash merger consideration applicable in the merger.

For purposes of calculating an NDRM price for use in expiration processing, OCC will use the following formula:

$$\text{NDRM} = 39.00$$

This formula includes an estimate for the value of the final net cash merger consideration per NDRM share based on the merger consideration amount before withholdings and not the actual net cash amount per share applicable in the merger.

**ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.**

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email [investorservices@theocc.com](mailto:investorservices@theocc.com). Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).